Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2005 June; 6(2): E298–E310.
Published online 2005 October 6. doi:  10.1208/pt060240
PMCID: PMC2750543

Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: A review


The purpose of this review is to give an insight into the considerable potential of lecithin organogels (LOs) in the applications meant for topical drug delivery. LOs are clear, thermodynamically stable, viscoelastic, and biocompatible jelly-like phases, chiefly composed of hydrated phospholipids and appropriate organic liquid. These systems are currently of interest to the pharmaceutical scientist because of their structural and functional benefits. Several therapeutic agents have been formulated as LOs for their facilitated transport through topical route (for dermal or transdermal effect), with some very encouraging results. The improved topical drug delivery has mainly been attributed to the biphasic drug solubility, the desired drug partitioning, and the modification of skin barrier function by the organogel components. Being thermodynamically stable, LOs are prepared by spontaneous emulsification and therefore posses prolonged shelf life. The utility of this novel matrix as a topical vehicle has further increased owing to its very low skin irritancy potential. Varied aspects of LOs viz formation, composition, phase behavior, and characterization have been elaborated, including a general discussion on the developmental background. Besides a comprehensive update on the topical applications of lecithin organogels, the review also includes a detailed account on the mechanistics of organogelling.

Keywords: organogel, lecithin, phospholipids, pluronic, topical delivery

Full Text

The Full Text of this article is available as a PDF (256K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Barr M. Percutaneous absorption. J Pharm Sci. 1962;61:395–409. doi: 10.1002/jps.2600510502. [Cross Ref]
2. Hadgraft J, Guy RH. Transdermal Drug Delivery: Development Issues and Research Initiatives. New York, NY: Marcel Dekker; 1989.
3. Asmussen B. Transdermal therapeutic systems—actual state and future developments. Methods Find Exp Clin Pharmacol. 1991;13:343–351. [PubMed]
4. Hadgraft J. Recent developments in topical and transdermal delivery. Eur J Drug Metab Pharmacokinet. 1996;21:165–173. doi: 10.1007/BF03190266. [PubMed] [Cross Ref]
5. Cevc G. Drug delivery across the skin. Expert Opin Investig Drugs. 1997;6:1887–1937. doi: 10.1517/13543784.6.12.1887. [PubMed] [Cross Ref]
6. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm. 1999;184:1–6. doi: 10.1016/S0378-5173(99)00095-2. [PubMed] [Cross Ref]
7. Mitchell DJ, Ninham BW. Micelles, vesicles and microemulsions. J Chem Soc Faraday Trans II. 1981;77:601–629. doi: 10.1039/f29817700601. [Cross Ref]
8. Cevc G, Paltauf E. Phospholipid Characterization, Metabolism and Novel Biological Applications. Champaign, IL: AOCS Press; 1995.
9. Attwood D, Florence AT. Surfactant, Systems: Their Chemistry, Pharmacy and Biology. London, UK: Chapman and Hall; 1983.
10. Kreuter J. Colloidal Drug Delivery Systems. New York, NY: Marcel Dekker; 1994.
11. Lawrence MJ. Surfactant systems: microemulsions and vesicles as vehicles for drug delivery. Eur J Drug Metab Pharmacokinet. 1994;19:257–269. doi: 10.1007/BF03188929. [PubMed] [Cross Ref]
12. Schwarz G. Basic kinetics of binding and incorporation with supramolecular aggregates. Biophys Chem. 1987;26:163–169. doi: 10.1016/0301-4622(87)80019-4. [PubMed] [Cross Ref]
13. Lehn MJ. Supramolecular chemistry: scope and perspectives (Molecules, Supramolecules and Molecular devices) Angew Chem Int Ed Engl. 1988;27:89–112. doi: 10.1002/anie.198800891. [Cross Ref]
14. Zarif L. Elongated supramolecular assemblies in drug delivery. J Control Release. 2002;81:7–23. doi: 10.1016/S0168-3659(02)00010-X. [PubMed] [Cross Ref]
15. Schmid MH, Korting HC. Liposomes: a drug carrier system for topical treatment in dermatology. Crit Rev Ther Drug Carrier Syst. 1994;11:97–118. [PubMed]
16. Abrol S, Trehan A, Katare OP. Formulation, characterization, and in vitro evaluation of silymarin loaded lipid microspheres. Drug Deliv. 2004;11:185–191. doi: 10.1080/10717540490433958. [PubMed] [Cross Ref]
17. De Miguel I, Imbertie L, Rieumajou V, Major M, Kravtzoff R, Betbeder D. Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers. Pharm Res. 2000;17:817–824. doi: 10.1023/A:1007504124603. [PubMed] [Cross Ref]
18. Donatella P, Cinzia AV, Steven N, Giovanni P, Massimo F. Lecithin microemulsions for the topical administration of ketoprofen: percutaneous adsorption through human skin and in vivo human skin tolerability. Int J Pharm. 2002;244:21–31. doi: 10.1016/S0378-5173(02)00295-8. [PubMed] [Cross Ref]
19. Stamatis H, Xenakis A. Biocatalysts using microemulsion-based polymer gels containing lipase. J Mol Catal. B Enzym. 1999;6:399–406. doi: 10.1016/S1381-1177(98)00142-8. [Cross Ref]
20. Scartazzini R, Luisi PL. Organogels from lecithins. J Phys Chem. 1988;92:829–833. doi: 10.1021/j100314a047. [Cross Ref]
21. Schurtenberger P, Scartazzini R, Magid LJ, Leser ME, Luisi PL. Structural and dynamic properties of polymer-like reverse micelles. J Phys Chem. 1990;94:3695–3701. doi: 10.1021/j100372a062. [Cross Ref]
22. Capitani D, Segre AL, Dreher F, Walde P, Luisi PL. Multinuclear NMR investigation of phosphatidylcholine organogels. J Phys Chem. 1996;100:15211–15217. doi: 10.1021/jp960811i. [Cross Ref]
23. Walde P, Giuliani AM, Boicelli CA, Luisi PL. Phospholipid-based reverse micelles. Chem Phys Lipids. 1990;53:265–288. doi: 10.1016/0009-3084(90)90026-N. [PubMed] [Cross Ref]
24. Shumilina EV, Khromova Y, Shchipunov YA. A study of the structure of lecithin organic gels by Fourier-transform IR spectroscopy. Zhurnal Fizicheskoi Khimii. 2000;74:1210–1219.
25. Cirkel P, Koper GJM. Proceedings of Conference on Colloid Chemistry: Memoriam Aladar Buzagh. Budapest, Hungary: Hungarian Chemical Society; 1996. The structure of lecithin organogels; pp. 36–39.
26. Schipunov YA. Lecithin organogel: a micellar system with unique properties. Colloids Surf A Physicochemical and Engineering Aspects. 2001;183–185:541–554. doi: 10.1016/S0927-7757(01)00511-8. [Cross Ref]
27. Shchipunov YA. Self-organizing structures of lecithin. Usp Khim. 1997;66:328–352.
28. Mezzasalma SA, Koper GJM, Shchipunov YA. Lecithin organogel as a binary blend of monodisperse polymer-like micelles. Langmuir. 2000;16:10564–10565. doi: 10.1021/la000860t. [Cross Ref]
29. Shchipunov YA. Lecithin organogels: rheological properties of polymer-like micelles formed in the presence of water. Colloid J. 1995;57:556–560.
30. Shchipunov YA, Shumilina EV. Lecithin bridging by hydrogen bonds in the organogel. In:Materials Science & Engineering C 3. 1995;43–50.
31. Shchipunov YA, Duerrschmidt T, Hoffmann H. End-to-end fusion of polymer-like micelles in the lecithin organogel under the action of an electric field. Langmuir. 2000;16:297–299. doi: 10.1021/la990810s. [Cross Ref]
32. Willimann H, Luisi PL. Lecithin organogels as matrix for transdermal transport of drugs. Biochem Biophys Res Commun. 1991;177:897–900. doi: 10.1016/0006-291X(91)90622-E. [PubMed] [Cross Ref]
33. Willimann H, Walde P, Luisi PL, Gazzaniga A, Stroppolo F. Lecithin organogels as matrix for transdermal transport of drugs. J Pharm Sci. 1992;81:871–874. doi: 10.1002/jps.2600810906. [PubMed] [Cross Ref]
34. Bhatnagar S, Vyas SP. Organogel-based systems for transdermal delivery of propranolol. J Microencapsul. 1994;2:431–438. doi: 10.3109/02652049409034260. [PubMed] [Cross Ref]
35. Dreher F, Walde P, Walther P, Wehrli E. Interaction of a lecithin microemulsion gel with human stratum corneum and its effect on transdermal transport. J Control Release. 1997;45:131–140. doi: 10.1016/S0168-3659(96)01559-3. [Cross Ref]
36. Dreher F, Walde P, Luisi PL, Elsner P. Human skin irritation of a soybean lecithin microemulsion gel and of liposomes. In:Proceedings Int Symp Control Rel Bioact Mater 22 Langmuir. 1995;640–641.
37. Dreher F, Walde P, Luisi PL, Elsner P. Human skin irritation studies of a lecithin microemulsion gel and of liposomes. Skin Pharmacol. 1996;9:124–129. [PubMed]
38. Hanahan DJ. A Guide to Phospholipid Chemistry. New York, NY: Oxford University Press; 1997.
39. Wendel A. Kirk-Othmer Encyclopedia of Chemical Technology. New York, NY: John Wiley & Sons; 1995. pp. 192–193.
40. Schneider M. Industrial production of phospholipids-lecithin processing. Lipid Technology. 1997;9:109–116.
41. Shumilina EV, Khromova Y, Shchipunov YA. Lecithin, organogels: the effect of phosphatidylethanolamine additives. Colloid J. 1997;59:514–518.
42. Moore J. Final report on the safety assessment of octyl palmitate, cetyl palmitate and isopropyl palmitate. J Am Coll Toxicol. 1982;1:13–35.
43. Sato K, Sugibayashi K, Morimoto Y. Effect and mode of action of aliphatic esters on the in-vitro skin permeation of micorandil. Int J Pharm. 1988;43:31–40. doi: 10.1016/0378-5173(88)90055-5. [Cross Ref]
44. Arellano A, Santoyo S, Martin C, Ygartua P. Influence of propylene glycol and isopropyl myristate on in vitro percutaneous penetration of diclofenac sodium from carbopol gel. Eur J Pharm Sci. 1999;7:129–135. doi: 10.1016/S0928-0987(98)00010-4. [PubMed] [Cross Ref]
45. Parsaee S, Sarbolouki MN, Parnianpour M. In vitro release of diclofenac diethylammonium from lipid-based formulations. Int J Pharm. 2002;241:185–190. doi: 10.1016/S0378-5173(02)00238-7. [PubMed] [Cross Ref]
46. Shchipunov YA, Shumilina EV. Lecithin organogels: role of polar solvent and nature of intermolecular interactions. Colloid J. 1996;58:117–125.
47. Shchipunov YA, Hoffmann H. Lecithin organogels with polar additives: rheological studies. Colloid J. 1998;60:794–799.
48. Berti JJ, Lipskys JJ. Transcutaneous drug delivery: a practical review. Mayo Clin Proc. 1995;70:581–586. doi: 10.4065/70.6.581. [PubMed] [Cross Ref]
49. Burnham R, Gregg R, Healy P, Steadward R. The effectiveness of topical diclofenac for lateral epicondylitis. Clin J Sport Med. 1998;8:78–81. doi: 10.1097/00042752-199804000-00002. [PubMed] [Cross Ref]
50. Giordano J, Daleo C, Sacks SM. Topical ondansetron attanuates nociceptive and inflammatory effects of intradermal capsaicin in humans. Eur J Pharmacol. 1998;354:R13–R14. doi: 10.1016/S0014-2999(98)00492-0. [PubMed] [Cross Ref]
51. Crandall WT, inventor.Topical moisturizing composition and method. US Patent 6 316 428. November 13, 2001.
52. Collett JH. Poloxamer. In: Popli H, Kibbe AH, editors. Handbook of Pharmaceutical Excipients. 3rd ed. London, UK: Pharmaceutical Press; 2000. pp. 386–388.
53. Shchipunov YA, Schmiedel P. Phase behavior of lecithin at the oil/water interface. Langmuir. 1996;12:6443–6445. doi: 10.1021/la960082y. [Cross Ref]
54. Shchipunov YA, Schmiedel P. Electrorheological phenomena in lecithin-decane-water mixtures. J Colloid Interface Sci. 1996;179:201–206. doi: 10.1006/jcis.1996.0203. [Cross Ref]
55. Shchipunov YA, Hoffmann H. Growth, branching and local ordering of lecithin polymer-like micelles. Langmuir. 1998;14:6350–6360. doi: 10.1021/la980469w. [Cross Ref]
56. Shchipunov YA, Shumilina EV, Ulbricht W, Hoffmann H. The branching of reversed polymer-like micelles of lecithin by sugar-containing surfactants. J Colloid Interface Sci. 1999;211:81–88. doi: 10.1006/jcis.1998.5927. [PubMed] [Cross Ref]
57. Shchipunov YA, Durrschmidt T, Hoffmann H. Electrorheological effects in lecithin organogels with water and glycerol. J Colloid Interface Sci. 1999;212:390–401. doi: 10.1006/jcis.1998.6046. [PubMed] [Cross Ref]
58. Shchipunov YA, Shumilina EV, Hoffmann H. Lecithin organogels with alkylglucosides. J Colloid Interface Sci. 1998;199:218–221. doi: 10.1006/jcis.1997.5313. [Cross Ref]
59. Shchipunov YA, Shumilina EV, Hoffmann H. Lecithin organogels with n-alkyl-D-glycosides and n-alkyl-D-lactobionamide. Colloid Polym Sci. 1998;276:368–372. doi: 10.1007/s003960050253. [Cross Ref]
60. Shchipunov YA, Hoffmann H. Thinning and thickening effects induced by shearing in lecithin solutions of polymer-like micelles. Rheologica Acta. 2000;39:542–553. doi: 10.1007/s003970000097. [Cross Ref]
61. Voit AV, Shchipunov YA. Dynamics of polymer-like lecithin micelles—rheological measurements. Colloid J. 2000;62:424–430.
62. Shchipunov YA, Mezzasalma SA, Koper GJM, Hoffmann H. Lecithin organogel with new rheological and scaling behavior. J Phys Chem B. 2001;105:10484–10488. doi: 10.1021/jp010874n. [Cross Ref]
63. Israelachvili JN, Mitchell DJ, Ninham BW. Theory of self assembly of hydrocarbon amphiphiles into micelles and bilayers. J Chem Soc Faraday Trans II. 1976;72:1525–1568. doi: 10.1039/f29767201525. [Cross Ref]
64. Seddon JM. Structure of the inverted hexagonal (H11) phase and non-lamellar phase transitions of lipids. Biochim Biophys Acta. 1990;1031:1–69. [PubMed]
65. Suzuki M, Nakajima Y, Yumoto M, Kimura M, Shirai H, Hanabusa K. In situ organogelation at room temperature: direct synthesis of gelators in organic solvents. Org Biomol Chem. 2004;2:1155–1159. doi: 10.1039/b401683a. [PubMed] [Cross Ref]
66. Schurtenberger P, Peng Q, Leser ME, Luisi PL. Structure and phase behaviour of lecithin-based microemulsions: a study of chain length dependence. J Colloid Interface Sci. 1993;156:43–51. doi: 10.1006/jcis.1993.1078. [Cross Ref]
67. Shioi A, Harada M, Tanabe M. Static light scattering from oil-rich microemulsions containing polydispersed cylindrical aggregates in sodium bis(2-ethylhexyl) phosphate system. J Phys Chem. 1995;99:4750–4756. doi: 10.1021/j100013a052. [Cross Ref]
68. Aboofazeli R, Barlow DJ, Lawrence MJ. Particle size analysis of concentrated phospholipid microemulsions. I. Total intensity light scattering. AAPS PharmSci. 2000;2:E13–E13. doi: 10.1208/ps020213. [PMC free article] [PubMed] [Cross Ref]
69. Zemb TN, Barnes IS, Derian PJ, Ninham BW. Scattering as a critical test of microemulsion structural models. Prog Colloid Polym Sci. 1990;81:20–29.
70. Terech P, Weiss RG. Low molecular mass gelators of organic liquids and the properties of their gels. Chem Rev. 1997;97:3133–3159. doi: 10.1021/cr9700282. [PubMed] [Cross Ref]
71. Simmons BA, Taylor CE, Landis FA, McPherson GL, Schwartz DK, Moore R. Microstructure determination of AOT+Phenol organogels utilizing small-angle X-ray scattering and atomic force microscopy. J Am Chem Soc. 2001;123:2414–2421. doi: 10.1021/ja0037926. [PubMed] [Cross Ref]
72. Gronwald O, Snip E, Shinkai S. Gelators for organic liquids based on self-assembly: a new facet of supramolecular and combinatorial chemistry. Curr Opinion Colloid Interface Sci. 2002;7:148–156. doi: 10.1016/S1359-0294(02)00016-X. [Cross Ref]
73. Abdallah DJ, Sirchio SA, Weiss RG. Hexatriacontane organogels. The first determination of the conformation and molecular packing of a low-molecular mass organogelator in its gelled state. Langmuir. 2000;16:7558–7561. doi: 10.1021/la000730k. [Cross Ref]
74. van Esch JH, Feringa BL. New functional materials based on self-assembling organogels: from serendipity towards design. Angew Chem Int Ed Engl. 2000;39:2263–2266. doi: 10.1002/1521-3773(20000703)39:13<2263::AID-ANIE2263>3.0.CO;2-V. [PubMed] [Cross Ref]
75. McAllister K, Sazani P, Adam M, et al. Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents. J Am Chem Soc. 2002;124:15198–15207. doi: 10.1021/ja027759q. [PubMed] [Cross Ref]
76. Schurtenberger P, Scartazzini R, Luisi PL. Viscoelastic properties of polymerlike reverse micelles. Rheologica Acta. 1989;28:372–381. doi: 10.1007/BF01336804. [Cross Ref]
77. Jibry N, Heenan RK, Murdan S. Amphiphilogels for drug delivery: formulation and characterization. Pharm Res. 2004;21:1852–1861. doi: 10.1023/B:PHAM.0000045239.22049.70. [PubMed] [Cross Ref]
78. Terech P. Kinetics of aggregation in steroid derivative/cyclohexane gelifying system. J Colloid Interface Sci. 1985;107:244–255. doi: 10.1016/0021-9797(85)90168-7. [Cross Ref]
79. Couffin-Hoarau A-C, Motulsky A, Delmas P, Leroux J-C. In situ-forming pharmaceutical organogels based on the self-assembly of L-Alanine derivatives. Pharm Res. 2004;21:454–457. doi: 10.1023/B:PHAM.0000019299.01265.05. [PubMed] [Cross Ref]
80. Nastruzzi C, Gambari R. Antitumor activity of (trans)dermally delivered aromatic tetra-amidines. J Control Release. 1994;29:53–62. doi: 10.1016/0168-3659(94)90121-X. [Cross Ref]
81. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89–121. doi: 10.1016/S0169-409X(00)00103-4. [PubMed] [Cross Ref]
82. Charles L, Matthew D, inventors.Cardiac glycosides for treating muscle pain and spasm. US patent appl publ 20030229029. December 11, 2003.
83. Friedman M, inventor,Treatment of bruxism. US patent 6 632 843. October 14, 2003.
84. Crandall WT, inventor.Method for topical treatment of scars with protein kinase C inhibitors. US patent 6 306 383. October 23, 2001.
85. Crandall WT, inventor,Method for topical treatment of carpal tunnel syndrome. US patent appl publ 20020164389. November 7, 2002.
86. Padilla M, Clark GT, Merill RL. Topical medications for orofacial pain: a review. J Am Dent Assoc. 2000;131:184–195. [PubMed]
87. Ford PR, inventor.Topical pain relief composition and carrier. US patent appl publ 20020028789. March 7, 2002.
88. Archer HK, Pettit MS, inventors. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery. PCT Int Appl WO2000045796. February 4, 2000.
89. Flores JA, Crowley KL, inventors.Process for the preparation of ketamine ointment. US patent 5 817 699. October 6, 1998.
90. Crandall WT, inventor.Composition and method for topical treatment of androgenic alopecia. US patent appl publ 20030049336. March 13, 2003.
91. Crandall WT, inventor.Transdermal transport of molecules. PCT Int Appl WO9803641. January 29, 1998.
92. Grace D, Rogers J, Skeith K, Anderson K. Topical diclofenac versus placebo: a double blind, randomized, clinical trial in patients with osteoarthritis of the knee. J Rheumatol. 1999;26:2659–2663. [PubMed]
93. Shippen E. Progesterone organogel for premenstrual dysphoric disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:262–263. doi: 10.1097/00004583-200103000-00002. [PubMed] [Cross Ref]
94. Kryger A, inventor. Topical testosterone formulations. PCT Int Appl WO2002055020. July 18, 2002.
95. Ciribassi JL, Luescher A, Pasloske KS, Robertson-Plouch C, Zimmerman A, Kaloostian-Whittymore L. Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats. Am J Vet Res. 2003;64:994–998. doi: 10.2460/ajvr.2003.64.994. [PubMed] [Cross Ref]
96. Aboofazeli RZ, Zia H, Needham TE. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement. Drug Deliv. 2002;9:239–247. doi: 10.1080/10717540260397855. [PubMed] [Cross Ref]
97. Hoffman SB, Yoder AR, Trepanier LA. Biovailability of transdermal methimazole in a pluronic lecithin organogel (PLO) in healthy cats. J Vet Pharmacol Ther. 2002;25:189–193. doi: 10.1046/j.1365-2885.2002.00405.x. [PubMed] [Cross Ref]
98. Bonina FP, Montenegro L, Scrofani N, et al. Effects of phospholipids based formulations on in vitro and in vivo percutaneous absorption of methyl nicotinate. J Control Release. 1995;34:53–63. doi: 10.1016/0168-3659(94)00125-E. [Cross Ref]
99. Agrawal GP, Juneja M, Agrawal S, Jain SK, Pancholi SS. Preparation and characterization of reverse micelle based organogels of piroxicam. Pharmazie. 2004;59:191–193. [PubMed]
100. Cadden B. Pharmaceutical compounding in pain medicine.NEPA Newsletter. 2000. Available at: Accessed: 26 July, 2004
101. Stafford Pharmacy and Home Healthcare. Information on natural hormone replacement therapy. 2003. Available at: Accessed: 26 July, 2004
102. Maxima Pharmaceuticals Inc. DiffusiMax and DiffusiMax Kit [Product Manual]. 2002. Edmonton, Canada: Maxima Pharmaceuticals Inc. Available at: Accessed: 26 July, 2004
103. J. A. R. Pharmaceuticals Limited. Phlojel and Phlojel Ultra. 2003. Edmonton, Canada: J.A.R. Pharmaceuticals Ltd. Available at: Accessed: 26 July, 2004
104. Speciality treatments. 2004. Available at: Accessed: 26 July, 2004
105. Reed’s RX Compounding Pharmacy Web site. Transdermal gels. 2004. Available at: Accessed: 26 July, 2004.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists